Page 98 - Read Online

Zhang et al. Cancer Drug Resist 2024;7:34 https://dx.doi.org/10.20517/cdr.2024.59 Page 9 of 20

Table 3. HNC cell drug resistance-related lncRNAs
Tumor lncRNA Cell line Expression Target Functions Corresponding Ref.
type level drugs
NPC TINCR NP69 N2Tert Up ACLY Activate TINCR-ACLY-PADI1- CDDP [111]
CNE-1, HK-1 MAPK-MMP2/9 axis
NPC NEAT1 C666-1, CNE-1, Up miR-129 Modulate the miR-129/Bcl-2 axis HDACis [112]
CNE-2
HNSCC HOTAI SCC25, Cal27, Up EZH2 Promote the growth of HNSCC CDDP/cetuximab [116]
UM1 cells.
HNSCC POP1-1 HN4, HN30 Up MCM5 Facilitate the repair of DNA damage CDDP [117]
LSCC FOXD2- Hep2, TU-212 Up STAT3 Promote STAT3 transcriptional CDDP [119]
AS1 activity
OSCC CYTOR CAL-27, SCC4 Up ceRNA Activate CYTOR/LPP axis CDDP [76]
OSCC HOXA11- HSC3, HSC4 Up microRNA- Facilitate tumor growth Dicoumarol [56]
AS 494
OSCC EGFR-AS1 primary cell Up / Resistance to EGFR TKIs TKIs [126]
cultures
PTC GLTC BCPAP, TPC-1, Up LDHA Resistance to RAI RAI [123]
KTC-1

HNC: Head and neck cancer; NPC: nasopharyngeal carcinoma; CDDP: cisplatin; HNSCC: head and neck squamous cell carcinoma; LSCC: laryngeal
squamous cell carcinoma; OSCC: oral squamous cell carcinoma; EGFR: epidermal growth factor receptor; TKIs: tyrosine kinase inhibitors; PTC:
papillary thyroid cancer; GLTC: glycolysis-associated regulator of LDHA post-transcriptional modification; LDHA: lactate dehydrogenase A; RAI:
radioiodine.

Figure 2. Overview of the main molecular mechanisms of lncRNAs in HNC drug resistance. HNC: Head and neck cancer.